Contract Manufacturing in India: Is the CMO Model a Viable Business? - Indian biologics manufacturers can tap into the global biologics market by enhancing their quality image and maintaining cost com

ADVERTISEMENT

Contract Manufacturing in India: Is the CMO Model a Viable Business?
Indian biologics manufacturers can tap into the global biologics market by enhancing their quality image and maintaining cost competitiveness.


BioPharm International
Volume 21, Issue 11

LOOKING AHEAD

India's actual and perceived shortcomings have together been detrimental to its ambitions in biologics manufacturing, even with respect to its main cost rival, China. These factors suggest that India is several years away from becoming a major destination for the outsourcing of biopharmaceutical manufacturing. In the long run, however, if Indian biologics manufacturers can establish a track record for recombinant products, enhance its quality image, maintain cost competitiveness, and demonstrate technology transfer and regulatory know-how, they are likely to be in the middle of the next boom in biologics manufacturing.

REFERENCES

1. Langer E, ed. Advances in biopharmaceuticals technology in India. Rockville, MD: Bioplan Associates; 2007.

2. Bioplan Associates. Top 60 biopharmaceutical organizations in India. Rockville, MD: BioPlan Associates. 2008.

3. Report sees boom time ahead for biopharma CMOs. Pharma http://Technologist.com/. 2005 Sep 15; cited 2008 Mar 8. Available from: http://www.in-pharmatechnologist.com/news/ng.asp?id=62535-outsourcing-contract-manufacturing-biopharmaceutical/.

4. Optimizing partnerships with contract organizations. Business Insights report. http://Reportbuyer.com/. 2007 Nov; cited 2008 Mar 8. Available from: http://www.reportbuyer.com/pharma_healthcare/healthcare/optimizing_partnerships_contract_organization.html.

5. Bioplan Associates. 5th Annual report and survey of biopharmaceutical manufacturing capacity and production. Rockville, MD: Bioplan Associates; 2008.

6. Downey W, Sopchak L. Evaluating supply and demand patterns for contract biologics manufacturing. Pharm Technol. 2007;31(8)Suppl: 24–33.

7. Biomanufacturing strategies. Business insights report (2007). http://Globalbusinessinsights.com/. Cited 2008 Mar 8. Available from: http://www.globalbusinessinsights.com/content/rbcr0003m.pdf.

8. 5th Annual report and survey. Rockville, MD. BioPlan Associates. 2008 Sep.

9. http://Pharmsource.com/. Stuck at the Dock? Cited 2008 Mar 8. Available from: http://www.pharmsource.com/blog/2007_03_01_pharmsource_archive.html.

10. Goodwin Bio to partner with Indian biopharma cos for contract manufacturing. Press release (2006 Feb 7). Cited 2008 Mar 8 2008. Available from http://www.goodwinbio.com/Pharmabiz.pdf.

11. http://Biocon.com/ [press archive on the internet]. Cited 2008 Mar 8. Available from: http://www.biocon.com/biocon_press_archive_news4.asp/.

12. Bharat http://Biotech.com/. [page on the internet]. Cited 2008 Mar 8. Available from: http://www.bharatbiotech.com/alliances.htm.

Eric Langer is president and managing partner at BioPlan Associates, Inc., Rockville, MD. He is also the editor of Advances in Biopharmaceutical Technology in India, 301.921.9074,


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

AbbVie/Shire Deal Officially Off
October 20, 2014
Amgen Sues Sanofi and Regeneron over Patent for mAb Targeting PCSK9
October 20, 2014
EMA Works to Speed Up Ebola Treatment
October 20, 2014
Lilly to Close Manufacturing Facility in Puerto Rico
October 17, 2014
BioReliance Introduces New Predictive Assays
October 17, 2014
Author Guidelines
Source: BioPharm International,
Click here